UGT1A9 and neoplasm: Although the metabolic activity and expression level of CYP3A4 and UGT1A9 were low exclusively in THLMs but not in NHLMs in our patients, the plasma concentrations of sorafenib and its metabolites probably depend on the volume of HCC tumor tissue and/or the surrounding cirrhotic tissue.